App-Based exercise may boost immune health in antibody deficiency
NCT ID NCT07698197
First seen Jul 13, 2026 · Last updated Jul 24, 2026 · Updated 3 times
Summary
This study tests whether a 12-week, app-guided exercise program is safe and practical for adults with primary antibody deficiencies—conditions where the immune system struggles to fight infections. Researchers will track how many people join and finish the program, how often they exercise, and whether it improves quality of life or immune function. The goal is to see if exercise can be a helpful addition to standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- app-based exercise program
- What this could lead to
- If successful, this could show that regular exercise is a safe, practical way to improve quality of life and immune function in people with primary antibody deficiencies.
- What could go wrong
- This is a small feasibility study with only 20 participants, so results may not apply to everyone. The program requires consistent app use, which may be challenging for some.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGG SUBCLASS DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bridgeport Hospital
RECRUITINGMilford, Connecticut, 06460, United States
-
Yale New Haven Health
RECRUITINGNorth Haven, Connecticut, 06473, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.